To determine association of circulating aberrations of androgen receptor as well as serum chromogranin A (CgA) in outcomes of Castration resistant prostatic cancer patients treated with Abiraterone and Enzalutamide

Trial Profile

To determine association of circulating aberrations of androgen receptor as well as serum chromogranin A (CgA) in outcomes of Castration resistant prostatic cancer patients treated with Abiraterone and Enzalutamide

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Mar 2017

At a glance

  • Drugs Abiraterone (Primary) ; Enzalutamide (Primary) ; Prednisone
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Mar 2017 New trial record
    • 18 Feb 2017 Results presented at the 2017 Genitourinary Cancers Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top